For Individual Investors in the US

Global Perspectives

Corporate Debt Index

The Corporate Debt Index is a study into trends in company indebtedness around the world.

Equity Perspectives

Quarterly insight from our equity teams to help clients navigate the markets and opportunities ahead.

Fixed Income Perspectives

Quarterly insight from our fixed income teams to help clients navigate the markets and opportunities ahead.

Global Dividend Index

The first of its kind, quarterly, long-term study into global dividend trends.

Sovereign Debt Index

The Sovereign Debt Index is a long-term study into trends in government indebtedness around the world, the investment opportunities this provides and the risks it presents.

LATEST INSIGHTS

Subscribe for relevant insights delivered straight to your inbox

Unlocking Value in Health Care Stocks

Unlocking Value in Health Care Stocks

Fewer COVID-related disruptions and less regulatory uncertainty could give overlooked areas of health care a boost in 2022.

Emerging markets now fertile ground for innovation

Emerging markets now fertile ground for innovation

While the pandemic has increased near-term risk, the rise of innovative and value-added industries should place the future trajectory of emerging markets on more stable footing, Daniel Graña and Matt Culley argue.

Despite Sell-Off, Health Care Fundamentals Appear Strong
Quick Views Healthcare

Despite Sell-Off, Health Care Fundamentals Appear Strong

Attractive valuations, continued innovation and an uptick in mergers and acquisitions could help lift the sector.

Drug-Pricing Reform an Uphill Battle
Quick Views Healthcare

Drug-Pricing Reform an Uphill Battle

Why the push for government-negotiated drug prices could prove to be a Sisyphean task.

Understanding the Impact of Delta

Understanding the Impact of Delta

The highly infectious variant of COVID-19 has led to rising case numbers, but we explain why a return to normalcy is still within striking distance.

Beating the Biotech Blues
Quick Views Healthcare

Beating the Biotech Blues

The sector is experiencing its worst period of relative underperformance on record. But some of history’s biggest biotech pains have been followed by memorable gains.

Innovation, Low Valuations Tailwinds for Health Care
Quick Views Healthcare

Innovation, Low Valuations Tailwinds for Health Care

Underperforming the broad market for the first half of 2021, health care now offers attractive valuations and significant growth potential, thanks to innovation.

The Affordable Care Act Lives On
Quick Views Healthcare

The Affordable Care Act Lives On

The Supreme Court’s decision to uphold the legislation may finally bring an end to challenges to the law and further expand health care in the U.S.

Biopharma’s Targeted Approach to Growth
Quick Views Healthcare

Biopharma’s Targeted Approach to Growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.

Making Sense of COVID-19 Vaccine IP Waivers

Making Sense of COVID-19 Vaccine IP Waivers

Why U.S. support for waiving intellectual property protections for COVID-19 vaccines does not spell the end of biotech growth.

Vaccines Prove Their Worth for Global Health Care

Vaccines Prove Their Worth for Global Health Care

In places where vaccination rates are rising, COVID-19 cases are dropping dramatically. What that means for ending the pandemic and health care long term.

Access to Medicine: The Need for Innovation, Partnerships and Data Capture

Access to Medicine: The Need for Innovation, Partnerships and Data Capture

How pharmaceutical companies are addressing the issue of inequitable access to medicine.